GlassScriptPhysician profile
Darshan A Patel
NPI 1518172535
$7,848.81
in general payments reported to CMS, 2019-2025
40 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $383 · 2021: $748 · 2022: $1,379 · 2023: $1,453 · 2024: $1,734 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,724 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,723.60 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,124.70 | 2021-2025 | |
| Sk Life Science, INC. | $1,034.34 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $764.28 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $736.12 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Emd Serono, INC. | $497.64 | 2019-2025 | Mavenclad |
| Janssen Pharmaceuticals, INC | $363.40 | 2020-2022 | |
| Abbvie INC. | $355.77 | 2022-2025 | |
| Biogen, INC. | $335.26 | 2020-2023 | Vumerity, Tysabri |
| Argenx US, INC. | $323.79 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $312.81 | 2020-2023 | Gammagard, Trintellix |
| Lundbeck LLC | $251.85 | 2024-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $171.53 | 2019 | |
| Pfizer INC. | $170.23 | 2025 | |
| Mallinckrodt Hospital Products INC. | $164.76 | 2020-2022 | |
| Genzyme Corporation | $160.32 | 2020-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Zeposia |
| Kyowa Kirin, INC. | $119.50 | 2020 | |
| Livanova USA, INC. | $118.62 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neurocrine Biosciences, INC. | $83.81 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $82.89 | 2024-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $75.87 | 2021-2022 | |
| Amgen INC. | $56.31 | 2024 | Uplizna, Repatha |
| Sumitomo Pharma America, INC. | $55.35 | 2023-2024 | Aptiom |
| Cranial Technologies, INC | $42.97 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $34.51 | 2025 | Daybue |
| Eisai INC. | $32.28 | 2019 | |
| Azurity Pharmaceuticals, INC. | $29.74 | 2023 | Eprontia |
| Forte Bio-Pharma LLC | $27.11 | 2025 | Tanlor |
| Sunovion Pharmaceuticals INC. | $25.52 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.53 | 2024 | Amvuttra |
| Exact Sciences Corporation | $24.36 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $18.59 | 2023 | Proquad, Vaxneuvance, M-M-R II |
| W. L. Gore & Associates, INC. | $18.30 | 2020 | |
| Neurelis, INC. | $18.06 | 2023 | Valtoco |
| Sanofi Pasteur INC. | $14.13 | 2019 | |
| Qiagen, LLC | $13.33 | 2019 | |
| Celgene Corporation | $13.30 | 2023 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $13.10 | 2022 | |
| Philips North America LLC | $11.25 | 2019 | |
| Travere Therapeutics, INC. | $3.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.